Drug interference in immunogenicity assays depends on valency

Journal of Pharmaceutical and Biomedical Analysis

Volumn 85, Issue , 2013, Pages 179-185

  Rispens, Theo ^a,b   Hart, Margreet H ^a,b   Ooijevaar de Heer, Pleuni ^a,b   van Leeuwen, Astrid ^c   Vennegoor, Anke ^d   Killestein, Joep ^d   Wolbink, Gerrit Jan ^a,b   van der Kleij, Desiree ^c  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Sanquin Diagnostiek   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti drug antibody (ADA); Bispecific antibody; Certolizumab; Drug interference; Natalizumab

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; IMMUNOGLOBULIN G4; MONOVALENT CATION; NATALIZUMAB;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG COMPETITION; DRUG DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MOLECULAR CLONING; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ABT; ADA; ANTI-DRUG ANTIBODY; ANTI-DRUG ANTIBODY (ADA); ANTIGEN BINDING TEST; BISPECIFIC ANTIBODY; CERTOLIZUMAB; DRUG INTERFERENCE; GSH; NATALIZUMAB; REDUCED GLUTATHIONE;

ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOLOGIC TECHNIQUES; POLYETHYLENE GLYCOLS;

EID: 84882688474     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.07.022     Document Type: Article

References (34)

1. Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., Van Riel P.L., Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Annals of the Rheumatic Diseases 2009, 68:1739-1745.
2. Bendtzen K., Geborek P., Svenson M., Larsson L., Kapetanovic M.C., Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis & Rheumatism 2006, 54:3782-3789.
3. Wolbink G.J., Vis M., Lems W., Voskuyl A.E., de G.E., Nurmohamed M.T., Stapel S., Tak P.P., Aarden L., Dijkmans B. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis & Rheumatism 2006, 54:711-715.
4. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., Dijkmans B.A., Aarden L., Wolbink G.J. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. Journal of the American Medical Association 2011, 305:1460-1468.
5. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S.O., Lems W.F., Aarden L., Dijkmans B.A., Tak P.P., Wolbink G.J. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Annals of the Rheumatic Diseases 2009, 69:817-821.
6. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., Dijkmans B.A., Tak P.P., Wolbink G.J. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the Rheumatic Diseases 2007, 66:921-926.
7. Pascual-Salcedo D., Plasencia C., Ramiro S., Nuno L., Bonilla G., Nagore D., Ruiz Del A.A., Martinez A., Aarden L., Martin-Mola E., Balsa A. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:1445-1452.
8. Baert F., Noman M., Vermeire S., Van A.G., D'Haens G., Carbonez A., Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. The New England Journal of Medicine 2003, 348:601-608.
9. Garces S., Demengeot J., Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Annals of the Rheumatic Diseases 2012, December 6.
10. van Schouwenburg P.A., Rispens T., Wolbink G.J. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nature Reviews Rheumatology 2013, 9:164-172.
11. Nechansky A. HAHA-nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. Journal of Pharmaceutical and Biomedical Analysis 2010, 51:252-254.
12. Allez M., Karmiris K., Louis E., Van A.G., Ben-Horin S., Klein A., Van der Woude J., Baert F., Eliakim R., Katsanos K., Brynskov J., Steinwurz F., Danese S., Vermeire S., Teillaud J.L., Lemann M., Chowers Y. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. Journal of Crohn's and Colitis 2010, 4:355-366.
13. Hart M.H., de V.H., Wouters D., Wolbink G.J., Killestein J., de Groot E.R., Aarden L.A., Rispens T. Differential effect of drug interference in immunogenicity assays. Journal of Immunological Methods 2011, 372:196-203.
14. van Schouwenburg P.A., Bartelds G.M., Hart M.H., Aarden L., Wolbink G.J., Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. Journal of Immunological Methods 2010, 362:82-88.
15. Bourdage J.S., Cook C.A., Farrington D.L., Chain J.S., Konrad R.J. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. Journal of Immunological Methods 2007, 327:10-17.
16. Lofgren J.A., Wala I., Koren E., Swanson S.J., Jing S. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. Journal of Immunological Methods 2006, 308:101-108.
17. Patton A., Mullenix M.C., Swanson S.J., Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. Journal of Immunological Methods 2005, 304:189-195.
18. Schmidt E., Hennig K., Mengede C., Zillikens D., Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. Clinical Immunology 2009, 132:334-341.
19. Lofgren J.A., Dhandapani S., Pennucci J.J., Abbott C.M., Mytych D.T., Kaliyaperumal A., Swanson S.J., Mullenix M.C. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. Journal of Immunology 2007, 178:7467-7472.
20. Sickert D., Kroeger K., Zickler C., Chokote E., Winkler B., Grenet J.M., Legay F., Zaar A. Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore. Journal of Immunological Methods 2008, 334:29-36.
21. Zhong Z.D., Dinnogen S., Hokom M., Ray C., Weinreich D., Swanson S.J., Chirmule N. Identification and inhibition of drug target interference in immunogenicity assays. Journal of Immunological Methods 2010, 355:21-28.
22. Vennegoor A., Rispens T., Strijbis E.M., Seewann A., Uitdehaag B.M., Balk L.J., Barkhof F., Polman C.H., Wolbink G., Killestein J. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Multiple Sclerosis 2013, 19:593-600.
23. Calabresi P.A., Giovannoni G., Confavreux C., Galetta S.L., Havrdova E., Hutchinson M., Kappos L., Miller D.H., O'Connor P.W., Phillips J.T., Polman C.H., Radue E.W., Rudick R.A., Stuart W.H., Lublin F.D., Wajgt A., Weinstock-Guttman B., Wynn D.R., Lynn F., Panzara M.A. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007, 69:1391-1403.
24. Lundkvist M., Engdahl E., Holmen C., Moverare R., Olsson T., Hillert J., Fogdell-Hahn A. Characterization of anti-natalizumab antibodies in multiple sclerosis patients. Multiple Sclerosis 2013, 19:757-764.
25. Labrijn A.F., Buijsse A.O., van den Bremer E.T., Verwilligen A.Y., Bleeker W.K., Thorpe S.J., Killestein J., Polman C.H., Aalberse R.C., Schuurman J., van de Winkel J.G., Parren P.W. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nature Biotechnology 2009, 27:767-771.
26. Rispens T., Leeuwen A., Vennegoor A., Killestein J., Aalberse R.C., Wolbink G.J., Aarden L.A. Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Analytical Biochemistry 2011, 411:271-276.
27. Rispens T., de V.H., de G.E., Wouters D., Stapel S., Wolbink G.J., Aarden L.A. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. Journal of Immunological Methods 2012, 375:93-99.
28. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M.A., Sandrock A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. The New England Journal of Medicine 2006, 354:899-910.
29. Choy E.H., Hazleman B., Smith M., Moss K., Lisi L., Scott D.G., Patel J., Sopwith M., Isenberg D.A. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002, 41:1133-1137.
30. Shapiro R.I., Plavina T., Schlain B.R., Pepinsky R.B., Garber E.A., Jarpe M., Hochman P.S., Wehner N.G., Bard F., Motter R., Yednock T.A., Taylor F.R. Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri((R))) with endogenous IgG4. Journal of Pharmaceutical and Biomedical Analysis 2011, 55:168-175.
31. J. Salfeld, D.J. Allen, H.R.J.M. Hoogenboom, Z. Kaymackalan, B. Labkovsky, J.A. Mankovitch, B.T. McGuinnis, A.J. Roberts, P. Sakorafas, D. Schoenhaut, T.J. Vaughan, M. White, A.J. Wilton, Human antibodies that bind human TNFa. 09/125098[WO97/29131], 1997. Ref Type: Patent.
32. van Schouwenburg P.A., van de Stadt L.A., de Jong R.N., van Buren E.E., Kruithof S., de G.E., Hart M., van Ham S.M., Rispens T., Aarden L., Wolbink G.J., Wouters D. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Annals of the Rheumatic Diseases 2013, 72:104-109.
33. van Schouwenburg P.A., Krieckaert C.L., Nurmohamed M., Hart M., Rispens T., Aarden L., Wouters D., Wolbink G.J. IgG4 production against adalimumab during long term treatment of RA patients. Journal of Clinical Immunology 2012, 32:1000-1006.
34. van Schouwenburg P.A., Krieckaert C.L., Rispens T., Aarden L., Wolbink G.J., Wouters D. Long term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Annals of the Rheumatic Diseases 2013, January 7.